[0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120]
1. Supportive Therapie
Zu den supportiven Maßnahmen gehören:
- Erythrozytensubstitution (Gabe von roten Blutkörperchen) nach klinischer Symptomatik- Thrombozytensubstitution nur bei schweren Blutungen
- infektiöse Komplikationen: Versuch der Infektlokalisation und Erregersicherung. Antibiotische Behandlung. Prophylaktischer Einsatz von Antibiotika nicht indiziert.
- Vermeidung nicht-steroidaler Antirheumatika (Acetylsalizylsäure, Diclofenac, Ibuprofen und andere) oder anderer, die Blutungsneigung verstärkender Medikamenten bei thrombozytopenischen Patienten
